首页> 外文期刊>Arthritis research & therapy. >Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate, and azathioprine.
【24h】

Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate, and azathioprine.

机译:多发性肌炎和皮肌炎患者的生存预测:皮质类固醇,甲氨蝶呤和硫唑嘌呤的作用。

获取原文
获取原文并翻译 | 示例
       

摘要

ABSTRACT: INTRODUCTION: The idiopathic inflammatory myopathies are rare diseases for which data regarding the natural history, response to therapies, and factors affecting mortality are needed. We performed this study to examine the effects of treatment and clinical features on survival in polymyositis and dermatomyositis patients. METHODS: 160 consecutive patients (77 polymyositis, 83 dermatomyositis) seen at the University of Michigan (1997-2003) were included. Medical records were abstracted for clinical, laboratory, and therapeutic data, including initial steroid regimen and immunosuppressive use. State vital records were utilized for mortality and cause of death data. Survival was modeled by left-truncated Kaplan-Meier estimation and Cox regression. RESULTS: 5- and 10-year survival estimates were 77% (95% CI 66, 85), and 62% (95% CI 48, 73), respectively; rates were similar for polymyositis and dermatomyositis. Survival between sexes was similar through 5-years, and thereafter significantly lower for males (10-year survival: 18% male, 73% female; p=0.002 for 5-10 year interval). The sex disparity was restricted to the polymyositis group. Increasing age at diagnosis and non-white race were associated with lower survival. Intravenous versus oral corticosteroid use was associated with a higher risk of death among whites (hazard ratio 10.6, 95% CI 2.1, 52.8). Early survival was similar comparing patients treated with methotrexate versus azathioprine, but survival at 10 years was higher for the methotrexate-treated group (76% vs. 52%, p=0.046 for 5-10 year interval). CONCLUSIONS: Patients treated initially with intravenous corticosteroids had higher mortality, likely related to disease severity. Both methotrexate and azathioprine showed similar early survival benefit as first line immunosuppressives; survival was higher between 5-10 years in the methotrexate-treated group but could not be confirmed in multivariable modeling for the full follow-up period. Other important predictors of long-term survival included younger age, female sex, and the Caucasian race.
机译:摘要:简介:特发性炎症性肌病是罕见的疾病,需要有关自然史,对治疗的反应以及影响死亡率的因素的数据。我们进行了这项研究,以检查治疗和临床特征对多发性肌炎和皮肌炎患者生存的影响。方法:纳入1997-2003年在密歇根大学连续诊治的160例患者(77例多发性肌炎,83例皮肌炎)。提取医疗记录以获取临床,实验室和治疗数据,包括最初的类固醇疗法和免疫抑制使用。利用国家生命记录记录死亡率和死因数据。通过左截短的Kaplan-Meier估计和Cox回归对存活率进行建模。结果:5年和10年生存率估计分别为77%(95%CI 66,85)和62%(95%CI 48,73)。多发性肌炎和皮肌炎的发生率相似。男女之间的生存期到5年相似,此后男性明显降低(10年生存期:男性18%,女性73%; 5-10年间p = 0.002)。性别差异仅限于多发性肌炎组。诊断时年龄增加和非白人种族与较低的生存率相关。静脉使用与口服皮质类固醇相比,白人的死亡风险更高(危险比10.6,95%CI 2.1,52.8)。比较接受甲氨蝶呤和硫唑嘌呤治疗的患者的早期生存率相似,但是甲氨蝶呤治疗组的10年生存率更高(5-10年间隔为76%比52%,p = 0.046)。结论:最初接受静脉内糖皮质激素治疗的患者死亡率较高,可能与疾病的严重程度有关。甲氨蝶呤和硫唑嘌呤均显示出与一线免疫抑制剂相似的早期生存获益。甲氨蝶呤治疗组的5至10年间生存率较高,但无法在整个随访期间的多变量模型中证实。长期生存的其他重要预测指标包括年龄,女性和白种人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号